Synthesis of potent and selective HDAC6 inhibitors led to unexpected opening of a quinazoline ring.
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
07 Apr 2022
07 Apr 2022
Historique:
received:
17
03
2022
accepted:
06
04
2022
entrez:
15
4
2022
pubmed:
16
4
2022
medline:
16
4
2022
Statut:
epublish
Résumé
Histone deacetylase (HDAC) inhibitors are highly involved in the regulation of many pharmacological responses, which results in anti-inflammatory and anti-cancer effects. In the present work, chemoinformatic analyses were performed to obtain two potent and selective aminotriazoloquinazoline-based HDAC6 inhibitors. We unexpectedly obtained an aminotriazole from a water-driven ring opening of the triazoloquinazoline scaffold. Both compounds were evaluated as HDAC6 inhibitors, resulting in subnanomolar inhibitory activity and high selectivity with respect to class I HDAC1 and HDAC8. Importantly, the compounds were about 3- and 15-fold more potent compared to the reference compound trichostatin A. Additionally, the predicted binding modes were investigated with docking. Considering that the aminotriazole scaffold has never been embedded into the chemical structure of HDAC6 inhibitors, the present study suggests that both the aminotriazoloquinazoline and aminotriazole classes of compounds could be excellent starting points for further optimization of potential anticancer compounds, introducing such novel groups into a relevant and new area of investigation.
Identifiants
pubmed: 35425078
doi: 10.1039/d2ra01753a
pii: d2ra01753a
pmc: PMC9006239
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11548-11556Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Int J Mol Sci. 2019 Feb 21;20(4):
pubmed: 30795625
Bioorg Med Chem. 2018 May 1;26(8):1418-1425
pubmed: 29500130
Nucleic Acids Res. 2021 Jul 2;49(W1):W326-W335
pubmed: 34023895
Curr Med Chem. 2021 Sep 02;:
pubmed: 34477503
J Org Chem. 2009 May 1;74(9):3540-3
pubmed: 19351173
J Enzyme Inhib Med Chem. 2021 Dec;36(1):2080-2086
pubmed: 34583596
ACS Omega. 2021 Aug 20;6(34):21843-21849
pubmed: 34497879
ChemistryOpen. 2021 Dec;10(12):1177-1185
pubmed: 34633754
Chem Biol Drug Des. 2019 Mar;93(3):232-241
pubmed: 30251407
J Med Chem. 2016 Feb 25;59(4):1455-70
pubmed: 26443078
ChemMedChem. 2008 Oct;3(10):1503-7
pubmed: 18792903
Chem Pharm Bull (Tokyo). 2009 Jun;57(6):580-5
pubmed: 19483337
Oncotarget. 2017 Jan 3;8(1):1845-1859
pubmed: 27659520
Epigenomics. 2015;7(1):103-18
pubmed: 25687470
Bioorg Med Chem Lett. 2009 Nov 15;19(22):6358-63
pubmed: 19833515
Bioorg Med Chem Lett. 2016 Oct 15;26(20):4955-4959
pubmed: 27650925
J Med Chem. 2019 May 9;62(9):4426-4443
pubmed: 30964290
J Comput Aided Mol Des. 2013 Mar;27(3):221-34
pubmed: 23579614
J Clin Invest. 2014 Jan;124(1):30-9
pubmed: 24382387
J Med Chem. 2006 Oct 19;49(21):6177-96
pubmed: 17034125
Eur J Med Chem. 2017 Jul 7;134:281-292
pubmed: 28419930
Nat Chem Biol. 2016 Sep;12(9):741-7
pubmed: 27454933
J Med Chem. 1996 Jul 19;39(15):2887-93
pubmed: 8709122
J Med Chem. 2020 Nov 12;63(21):12460-12484
pubmed: 32608981
Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954
pubmed: 27899562
Expert Opin Ther Pat. 2020 Apr;30(4):263-274
pubmed: 32008402
Bioorg Med Chem. 2014 Aug 1;22(15):4135-50
pubmed: 24980703
Nat Genet. 2003 Mar;33 Suppl:245-54
pubmed: 12610534
Bioorg Med Chem. 2022 Jan 1;53:116524
pubmed: 34847495
Future Med Chem. 2018 Jul 1;10(13):1545-1553
pubmed: 29766737
Biomed Pharmacother. 2020 Nov;131:110607
pubmed: 32841898
J Chem Inf Comput Sci. 1998 May-Jun;38(3):511-22
pubmed: 9611787
Eur J Med Chem. 2021 Jan 1;209:112887
pubmed: 33035922